Introduction
Vitiligo is a skin disease distinguished by complete but selective loss of melanocytes from the epidermis. Its main etiology is still obscure. Some theories include autoinflammatory, autoimmune, neural, genetic, cytotoxic, and metabolic etiologies [1] . Lately, there has been a rising awareness regarding the role of the active form of vitamin D, 1,25-dihydroxyvitamin D 3 [1, 25(OH) D] , in the pathogenesis of vitiligo and its impact in the treatment of this disorder [2] .
The main role of vitamin D -besides bone formation and calcium metabolism -is the interplay with the immune system, having its receptors expressed in activated CD8+ and CD4+ T cells, B cells, dendritic cells, neutrophils, and macrophages [3] . Low vitamin D levels have been linked to numerous autoimmune diseases, such as multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, and undifferentiated connective tissue disease. Bearing in mind that vitiligo is an autoimmune disease, it could, therefore, be provoked or exacerbated by low vitamin D levels. The link between vitiligo and vitamin D levels still needs to be investigated more thoroughly. Whether a deficit in vitamin D levels plays a role in inducing vitiligo, as it does in other autoimmune disorders, is not yet clear [1] .
Worthy of note, it has been demonstrated that an elevated expression of the proinflammatory cytokine interleukin (IL)-17, either in peripheral blood or tissues, contributes to the pathogenesis of vitiligo [4] . IL-17-secreting T cells (Th17 cells) are greatly influenced by vitamin D. It has been suggested that vitamin D could cause immunomodulatory effects by restraining IL-17 formation through direct transcriptional inhibition of IL-17 gene expression [5] .
Our review of previously published data regarding the association between vitamin D, IL-17, and vitiligo revealed that -to date and to the best of our knowledgenobody has assessed such a link. We, therefore, aimed to evaluate a possible regulatory effect of vitamin D on IL-17 in patients with nonsegmental vitiligo (NSV) as well as to investigate its relation to disease activity.
Materials and Methods
This is a cross-sectional study that comprised 30 patients (21 females and 9 males) with NSV and 40 healthy volunteers. For further details, see the supplementary materials (for all online suppl. material, see www.karger.com/doi/10.1059/000479925 [6] [7] [8] [9] [10] [11] (Fig. 1) .
Results

Serum Level of IL-17 and Its Relation to the Different Demographic Data in the Patient Group
In comparison to the control group, we recorded significantly higher serum levels of IL-17 among vitiligo patients (mean ± SD 17.48 ± 8.7 ng/mL) versus controls (12.48 ± 3.33 ng/mL) (p = 0.001). In vitiligo patients, serum IL-17 levels showed a nonsignificant difference as regards sex, skin phototype, family history, associated stressful condition, disease activity, and clinical type of the disease (Table 1) .
Analyzing the correlation between the serum levels of IL-17 and each individual demographic data revealed an insignificant correlation between IL-17 and age (r = -0.317, p = 0.088), duration (r = -0.264, p = 0.159), and extent of the disease (r = -0.228, p = 0.225).
When multivariate linear regression was performed to analyze the correlation between IL-17 and the different demographic data of the patients, we found a nonsignificant correlation between IL-17 and each of the independent variables in the presence of other variables (Table 2 ).
Serum Level of 1,25(OH)D and Its Relation to the Different Demographic Data in the Patient Group
We noted significantly lower serum levels of vitamin D among vitiligo patients (mean ± SD 13.81 ± 3.55 ng/ mL) versus controls (23.76 ± 10.31 ng/mL) (p < 0.001). In vitiligo patients, serum vitamin D levels showed a nonsignificant difference as regards sex, skin phototype, family history, associated stressful condition, disease activity, and clinical type of the disease (Table 1) .
Analyzing the correlation between the serum levels of vitamin D and each individual demographic data revealed a significant positive correlation between vitamin D and disease duration (r = 0.381, p = 0.038) as the longer the disease duration, the higher were the serum levels of vitamin D (Fig. 2 ). However, we noted an insignificant correlation between vitamin D levels and age (r = 0.144, p = 0.448) and extent of the disease (r = -0.163, p = 0.389). Furthermore, no significant correlation was noted between IL-17 and vitamin D serum levels (r = -0.101, p = 0.597).
Multivariate linear regression was performed to evaluate the relationship between serum vitamin D levels in patients with the different demographic data and revealed a nonsignificant relationship (Table 2) .
Serum vitamin D concentrations were further divided as deficient (<10 ng/mL), insufficient (10-30 ng/mL), and sufficient (≥30 ng/mL) in both patients and controls. Of the 30 vitiligo patients included in the study, 5/30 (16.7%) patients had deficient vitamin D levels versus 0/40 (0%) controls, and 25/30 (83.3%) patients had insufficient vi-70 included subjects 40 controls 30 NSV patients 10 mL venous blood was drawn to determine the serum 1,25-dihydroxyvitamin D 3 and IL-17 levels 10 mL venous blood was drawn to determine the serum 1,25-dihydroxyvitamin D 3 and IL-17 levels tamin D serum levels versus 34/40 (85%) controls. Meanwhile, none of the patients (0%) had sufficient vitamin D levels versus 6/40 (15%) controls. Insufficient vitamin D serum levels were significantly lower in the control group versus the patient group (p < 0.001) ( Table 3) .
Discussion
The present study points to a potential involvement of vitamin D in the pathogenesis of vitiligo as well as reconfirming the critical role played by IL-17 in such disease. This inference was based on our results, which demonstrated a significantly lower serum level of 1,25(OH)D and a significantly higher serum level of IL-17 in patients compared to controls. A significant correlation between both these alleged culprits could not be detected, however, in either patients or controls. On the other hand, a significant positive correlation between serum levels of vitamin D and disease duration was found. Otherwise, there were no significant correlations between the studied parameters and the clinical or demographic data of patients or controls.
A link between vitamin D deficiency and vitiligo was suggested by Nunes and Martins [12] . This was followed by a preliminary study conducted by Silverberg et al. [13] , who demonstrated low serum levels of vitamin D in patients with vitiligo; the authors concluded that evaluating serum level of vitamin D could aid in the detection of associated autoimmune diseases. These findings were in concordance with those of another study conducted on vitiligo patients, in which low serum levels of vitamin D were detected [14] . Our results were in agreement with the previous studies as regards vitamin D being one of the recruited arms in the complex pathogenesis of vitiligo.
The significantly higher serum level of IL-17 in our patients in comparison to controls was also demonstrated by other studies [15] [16] [17] , which emphasizes the potentially pivotal role played by this proinflammatory cytokine in the perpetuation of the autoimmune-mediated destruction of melanocytes.
The exact etiopathogenesis of vitiligo is a controversial issue. Both cellular and humoral immune responses are claimed to be responsible for a cascade of inflammatory reactions that mediate the loss of melanocytes. Overproduction of proinflammatory cytokines has been demonstrated in vitiligo, including TNF-α, IL-6, and IL-2 [18] . An immune-modulating role of vitamin D has been shown through the regulation of vital processes of cells belonging to the innate and adaptive immune systems [19, 20] . Moreover, vitamin D has inhibitory effects on B Data are presented as mean ± SD. * p value is statistically significant. and T cells as well as several proinflammatory cytokines known to be involved in vitiligo [21] . In addition, vitamin D may activate the differentiation of melanocyte precursors and regulate melanogenesis [22] . Recently, it has been highlighted that the addition of 1,25(OH)D to cultured human epidermal melanoblasts has increased endothelin B receptors in a dose-dependent manner [23] . Endothelin B receptor has been shown to be a key factor through which vitamin D exerts its modulatory action on the proliferation and differentiation of mouse melanoblasts [22] . Another explanation for the lower vitamin D levels in vitiligo patients could be attributed to their tendency to avoid sun exposure; however, we excluded all subjects (patients and controls) with a history of prolonged sun exposure (e.g., outdoor workers, excessive outdoor activities, …) from this study in order to eliminate this important factor of sun exposure.
A relationship between vitamin D and IL-17 has been suggested, in which the former comprises a regulatory action on the latter. This helps to restore the TH17-Tregs immune balance which has a protective effect against autoimmune diseases [24] . However, the lack of such correlation in the present study does not abolish its possible existence, with respect to the intertwined and multi-factorial pathogenic mechanisms in vitiligo. In addition, the relatively limited number of recruited patients and controls could be another reason for our inability to demonstrate such association.
Khurrum and AlGhamdi [1] found that there was no difference in vitamin D serum levels between vitiligo patients and controls. The authors added that vitamin D deficiency within vitiligo patients was more manifest in those with younger age, male gender, short disease duration, and lack of phototherapy. Ustun et al. [3] also found no significant difference in serum levels of vitamin D between vitiligo patients and controls, despite the insufficient and/or very low levels in the majority of their patients. These differences among the previous two studies and ours could be attributed to the different number of patients and control subjects enrolled in each one. The geographic and cultural diversity could also account for such variation in results. Nevertheless, the latter study did mention that the majority of vitiligo patients had vitamin D deficiency. Such controversy warrants further studies on vitamin D in vitiligo patients.
In accordance with our results, Takci et al. [14] demonstrated significantly lower vitamin D serum levels in vitiligo patients than controls. They also detected a universal lack of vitamin D in the Turkish population, where 72% of patients had deficient vitamin D levels versus 30% of controls. In our study, approximately 17% of patients had deficient vitamin D versus 0% of controls, but 83% of patients and 85% of controls had insufficient levels. Such a finding raises the possibility of general vitamin D insufficiency among the Egyptian population and requires further larger-scale studies. The Turkish authors showed a significant negative correlation between vitamin D levels and age of patients as well as the presence of autoimmune comorbidities. Such a correlation was not found among our patients. Surprisingly, a significant positive correlation between serum levels of vitamin D and disease duration was demonstrated among our patients. This result was shared by Khurrum and AlGhamdi [1] , where both authors found lower levels of vitamin D in patients with a shorter duration of vitiligo (<15 months). This could be explained by the notion that vitamin D levels might be lowered by factors other than disease duration, such as disease activity. In other words, a longer disease duration might account for a higher chance of stability and, accordingly, higher vitamin D levels, while a shorter duration might point to an active disease with lower vitamin D levels.
In conclusion, vitamin D represents a potential player in the complex pathogenesis of vitiligo. Its possible regulatory relation with IL-17 as a proinflammatory cytokine involved in such disease, together with its real weight as a screening tool for susceptibility of vitiligo, is worthy of further analysis and evaluation. Studying the effect of vitamin D supplements in active versus stable vitiligo, with a large number of patients, should be considered.
